BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24439226)

  • 1. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
    Lok T; Chen L; Lin F; Wang HL
    Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
    Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
    Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
    Hedegaard Jensen G; Mortensen MB; Klöppel G; Nielsen MFB; Nielsen O; Detlefsen S
    Pathol Res Pract; 2020 May; 216(5):152925. PubMed ID: 32273198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
    Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
    Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
    Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
    Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy.
    Schmidt MT; Himmelfarb EA; Shafi H; Lin F; Xu H; Wang HL
    Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):478-87. PubMed ID: 22495381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.
    Lin F; Shi J; Liu H; Hull ME; Dupree W; Prichard JW; Brown RE; Zhang J; Wang HL; Schuerch C
    Am J Surg Pathol; 2008 Jan; 32(1):78-91. PubMed ID: 18162774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder.
    Shi J; Liu H; Wang HL; Prichard JW; Lin F
    Hum Pathol; 2013 Apr; 44(4):503-11. PubMed ID: 23079206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
    Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
    Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
    Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
    Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of von Hippel-Lindau gene product (pVHL) and S100P in cystic neoplasms of the pancreas--with an implication for their roles in tumorigenesis.
    Liu H; Shi J; Wang HL; Zhang J; Brown RE; Wilkerson M; Lin F
    Ann Clin Lab Sci; 2012; 42(2):109-17. PubMed ID: 22585604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology.
    Kosarac O; Takei H; Zhai QJ; Schwartz MR; Mody DR
    Acta Cytol; 2011; 55(2):142-8. PubMed ID: 21325798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100P is a novel marker to identify intraductal papillary mucinous neoplasms.
    Nakata K; Nagai E; Ohuchida K; Hayashi A; Miyasaka Y; Aishima S; Oda Y; Mizumoto K; Tanaka M; Tsuneyoshi M
    Hum Pathol; 2010 Jun; 41(6):824-31. PubMed ID: 20153506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of S100p, IMP3, Maspin, and pVHL in the Differantial Diagnosis of Pancreatic Ductal Adenocarcinoma and Normal/chronic Pancreatitis in Fine Needle Aspiration Biopsy.
    Aksoy-Altinboga A; Baglan T; Umudum H; Ceyhan K
    J Cytol; 2018; 35(4):247-251. PubMed ID: 30498299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
    Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
    Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of maspin in distinguishing adenocarcinoma from benign biliary epithelium on endoscopic bile duct biopsy.
    Chen L; Huang K; Himmelfarb EA; Zhai J; Lai JP; Lin F; Wang HL
    Hum Pathol; 2015 Nov; 46(11):1647-54. PubMed ID: 26362203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.
    Hooper JE; Morgan TK; Grompe M; Sheppard BC; Troxell ML; Corless CL; Streeter PR
    Hum Pathol; 2012 Oct; 43(10):1583-9. PubMed ID: 22406361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer.
    Yang Z
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):19-25. PubMed ID: 25153498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.
    Chen YL; Jeng YM; Hsu HC; Lai HS; Lee PH; Lai PL; Yuan RH
    Int J Surg; 2013; 11(1):85-91. PubMed ID: 23246869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.